MGMT and neoplasm: However, the MGMT status is mainly assessed based on tumor samples by pyrosequencing, methylation-specific polymerase chain reaction (PCR) or methylation chip analysis [6–8], and these methods are restricted by comparatively long detection periods and high detection costs, the existence of intratumor heterogeneity, and the unattainability of tumor samples through surgery or biopsy.